GRAIL today announced leadership changes to support the company’s next phase of growth as it moves towards commercialisation of early detection products.
Chief Medical Officer at Intel, John Sotos has expressed his fears of a potential attack on people’s genomes by hackers, through the use of bioweapons.
Invitae acquires Good Start Genetics and CombiMatrix – two acquisitions to establish a leading position in family health genetic information service.
Lab testing and equipment company, Theranos has announced that it’s settled a reported $140 million lawsuit from Walgreens.
The GP-Write team have separately begun to either rewrite the yeast genome or create new yeast DNA codes to be put into yeast cells.
Oral treatment for leukaemia produced by Celgene Corp and Agios Pharamaceuticals has been approved by the US Food and Drug Administration (FDA).
In the towns of Hildale and Colorado City on the Arizona-Utah border in the US, they’re struggling with a health crisis caused by a recessive gene.
Ed You is an agent from the Federal Bureau of Investigation, who is at the forefront of the genetic dispute between the US and China.
Law firm Robins Geller Rudman & Dowd has filed a class action lawsuit against Foundation Medicine.
GlaxoSmithKline is struggling to compete in producing treatments for rare diseases, at a time when rivals are increasing their market presence.
Helix’s new sequencing platform is designed to turn a one-time genetic donation into a lifetime of insights, all for $80.
Reports of successful genetic modification of human embryos raise questions about how we should react.
Researchers have turned their attention to tumour mutation clusters, to discover clues to the mutagenic processes contributing to various cancer types.
Researchers in the U.S. have demonstrated that they can efficiently improve the DNA of human embryos using the gene-editing technique CRISPR.
French biotech Cellectis has announced that the European Patent Office has granted them a patent to use CRISPR in T cells.